An Open‐Label Phase II Trial of Bevacizumab plus Docetaxel and Gemcitabine in Advanced, Previously Untreated Nonsquamous Non‐Small Cell Lung Cancer

Conclusion.Docetaxel, gemcitabine, and bevacizumab at this dose and schedule resulted in excessive toxicity. Despite promising efficacy, in light of efficacious and safe alternative therapies, this regimen should not be used to treat advanced NSCLC.

Source: The Oncologist - April 10, 2019 Category: Cancer & Oncology Authors: Pradnya Dinkar Patil, Marc Shapiro, Nooshin Hashemi Sadraei, Nathan A. Pennell Tags: Lung Cancer, Chinese Edition, Clinical Trial Results Source Type: research